Upload
gillian-bridges
View
224
Download
1
Tags:
Embed Size (px)
Citation preview
Tuberculosis
What is Tuberculosis?
PrevalencePrevalence
Tuberculosis is a bacterial infection that causes more deaths in the world than any other disease.
About 2 billion people are infected with the bacilli and about 2 million people die annually.
8 to 9 million deaths occur d/t TB
14,000 new cases in the U.S. each year
Tuberculosis (TB)Tuberculosis (TB)
Caused by:Mycobacterium tuberculosis
In the United States:Rates decliningIncidence decreased with:
Improved sanitationSurveillance Treatment of people with active disease
Rates still high in selected populations
The Disease Process:Chronic and recurrentAffects the lungsCan invade any organ
Resurgence of Tuberculosis!!Resurgence of Tuberculosis!!
1980s and 1990sCauses
HIV AIDSMultiple drug resistant strainsSocial Factors
ImmigrationPovertyHomelessnessDrug Use
Continues to declineTB-control programsInitiation and completion of appropriate medications
Worldwide TBWorldwide TB
Countries that account for 90% of world cases of TB
Countries of AsiaAfricaMiddle EastLatin America
In Austin, TexasLarge number of immigrants, college students, and visitors from:
IndiaMiddle EastLatin America
Other Risk Factors for TBOther Risk Factors for TB
Overcrowded ConditionsNursing homes, rehabilitation facilities and hospitalsHomeless sheltersDrug treatment centers and prisons
People with Altered Immune FunctionsOlder adultsPeople with AIDSPeople on chemotherapy
Spreading the DiseaseSpreading the Disease
Mycobacterium tuberculosisSlow-growing, rod shaped, acid fast bacillus***Waxy outer capsule which makes it resistant to destruction
TransmissionInfectious person
Coughs, sneezes, sings, or talks
Airborne dropletsRemain suspended in the air for several hours
Susceptible HostBreaths in microorganismNormal defenses of the upper respiratory system do not protect.
Ask Yourself?Ask Yourself?
Can the disease be spread by:
Hands
Books
Glasses
Dishes
Clothing
Bedding
Risk For InfectionRisk For Infection
Characteristics of the Infected PersonTB is active How much of the lung is involvedCoughing
Extent of Contamination of the AirOvercrowded conditionsAir circulation
Susceptibility of the HostImmuno-compromisedNutritionHealth
Infection Takes HoldInfection Takes HoldMinute droplet nuclei inhaled
Upper lobeLodges in alveolus or bronchioleLeads to inflammation
Neutrophils and macrophages isolate seal off but cannot destroySealed off colony of bacilli (tubercle)
Inside infected tissue diesCreating a cheese-like center
The Immune ResponseThe Immune Response
Adequate– Scar tissue encapsulates the bacilli
Inadequate– Tuberculosis develops– Extensive lung destruction can occur– Spread by the blood to other organs
• Genitourinary tract• Brain (meningitis)• Skeletal
Common Sites of TB DiseaseCommon Sites of TB Disease
Lungs – most common
Pleura
Bones and joints
Lymphatic system
Genitourinary systems
Central nervous system
Disseminated (miliary TB)
Tuberculosis Can Spread within Tuberculosis Can Spread within the Bodythe Body
Tuberculosis InfectionTuberculosis InfectionThe bacteria is inhaled but the immune system encapsulates the bacteria preventing it from becoming active and progressing to a disease.
TB infection that does not have an active case is not considered a case of TB, but referred to as latent TB.
TB tubercle usually stays inactive for life, a small percent converts to active disease
Tuberculosis DiseaseTuberculosis Disease
• The immune system is not sufficient to stop the disease so active bacteria multiply and cause clinically active disease.
Signs & SymptomsSigns & Symptoms
Fatigue, malaise (late afternoon)Low grade fever, night sweatsAnorexia, weight lossHemoptysisFrequent productive cough
mucoid or mucopurulent
Tight, dull chestJoint pain
ComplicationsComplications
Pleural effusion and empyema–Caused by bacteria in pleural space–Inflammatory reaction with plural
exudates of protein-rich fluid
TB pneumonia–Large amounts of bacilli discharging
from granulomas into lung or lymph nodes
Skin TestingSkin Testing
Tuberculin Skin Test (Mantoux)positive test does not signify active disease
0.1 ml PPD intradermally
Read in 48-72 hours
Administering the Tuberculin Skin TestAdministering the Tuberculin Skin Test
Inject intradermally 0.1 ml of 5TU PPD tuberculin
Produce wheal 6 mm to 10 mm in diameter
Do not recap, bend, or breakneedles, or remove needles from syringes
Follow universal precautions for infection control
ResultsResults
• Measure induration– Positive 10 mm– Possible 5-9 mm– Negative 0-4
• Repeat x2 or x3 if any clinical signs25% false negative
DiagnosingDiagnosing
• Skin test positive 3-12 weeks after exposure
• Chest x-ray
• Sputum - Acid Fast Bacillus (AFB)– Smear not definitive– Culture is only definitive diagnosis
• May need up to 8 weeks to grow
Chest X-RayChest X-Ray
•Abnormalities often seen in apical or posterior segments of upper lobe or superior segments of lower lobe
•May have unusual appearance in HIV-positive persons
•Cannot confirm diagnosis of TB
Arrow points to cavity in patient's right upper lobe.
CulturesCultures
Use to confirm diagnosis of TB
•Culture all specimens, even if smear negative
•Results in 4 to 14 days when liquid medium systems used
Colonies of M. tuberculosis growing on media
Newly converted to positive Newly converted to positive PPDPPD
• Isoniazid 300 mg X 6-9 months prophylactive prevents active Tb
Drug TherapyDrug Therapy
• Active disease– Patients should be taught about side effects and
when to seek medical attention (see Lewis p.573)– Liver function should be monitored
• Latent TB infection– Individual is infected with M. tuberculosis, but is not
acutely ill– Usually treated with INH for 6 to 9 months– Patients with HIV should take INH for 9 months
MedicationsMedications
• Newly diagnosed clients with active disease typical treated with four medications– isoniazid (INH) oral 300 mg daily or 900 mg twice a
week.– rifampin oral 600 mg daily or twice a week– pyrazinamide (PZA) oral 15 to 30 mg/kg up to 2G per
day or 30 to 70 mg/kg once a week• minimum 9 months• take in AM• 90% have negative sputum in 3 months
– ethambutal oral 15 mg/kg daily• Other medications
– rifabutin– rifapentine
Drug Side effects Nursing Implications
Isoniazid (INH) Noninfections hepatitisPeripheral neuropathyHypersensitivity
Give B6 pyridoxine as prophylactic against peripheral neuropathy
Assess for S&S of hepatitis (jaundice, yellow skin, dark urine, clay colored stools, pruritis)
Rifampin (Rifadin) GI disturbancesOrange discoloration of body fluids (sputum, urine, sweat, tears)
Inform patient about orange discoloration of fluids/ urine
Ethambutol Retrobulbar neuritis (decreased red-green color discrimination)
Get a baseline Snellen vision test and color discrimination and monthly when on high doses
Pyrazinamide (PZA)
Hepatoxicity, polyarthritis,Skin rash, hyperuricemia
Assess for S&S of hepatitis (jaundice, yellow skin, dark urine, clay colored stools, pruritis)
IsoniazidIsoniazid
• Most effective TB drug• Take in AM with food• Continue until sputum negative 6 months• Adverse Effects:
– peripheral neuropathy – hepatitis
• Monitor– Liver Functions Studies (AST and ALT)– Avoid hepatotoxins (ETOH, acetaminophen)
RifampinRifampin
• Take on empty stomach• Monitor liver function tests• Can cause:
– Hepatitis– Suppression of oral contraceptives– Do not stop medication
• Will cause flu-like syndrome and fever when resumed
• Colors body fluids– Sweat urine saliva tears: turn orange-red
PyrazinamidePyrazinamide
• Increase fluids• Take with food• Adverse Effects
– Hepatotoxicity– Hyperuricemia
• Monitor– Uric acid levels– AST and ALT– Avoid hepatotoxins (ETOH; Tylenol)
EthambutolEthambutol
• Protect from light
• Adverse effects: retrobulbar neuritis, skin rash, reversible with discontinuation of the drug
• Monitor color vision and acuity
Symptoms of Liver ToxicitySymptoms of Liver Toxicity
loss of appetite
N/V
dark urine
jaundice
malaise
unexplained elevated temperature for longer than 3 days
abdominal tenderness
Close Monitoring While Taking Close Monitoring While Taking Antituberculosis MedicationsAntituberculosis Medications
Monitor liver functions
Regular office visits
Check for complianceRifampin
Check color of urine
INHCheck urine for metabolites
Give medicationTwice week in the office if compliance is a problem
Monitoring Response to Treatment
Monitor patients bacteriologically monthly until cultures convert to negative
After 3 months of therapy, if cultures are positive or symptoms do not resolve, reevaluate for
Potential drug-resistant disease
Nonadherence to drug regimen
If cultures do not convert to negative despite 3 months of therapy, consider initiating DOT
Monitoring Response to Monitoring Response to TreatmentTreatment
• The patient asks how long before The patient asks how long before he can be considered non-he can be considered non-contagious?contagious?
• Answer: The patient is considered infectious until three sputum smears are negative for acid-fast bacilli.
When can a TB patient be When can a TB patient be considered noninfectious? considered noninfectious?
When they meet all three criteria (CDC)
•Received adequate TB treatment for a minimum of two weeks
•Symptoms have improved
•Has three consecutive negative sputum smears from sputum collected in an 8-24 hr interval (one being early morning specimen)
Answer thisAnswer this
How would the nurse assess if the patient has been compliant with taking their medications?
Urine would be orangeCultures would be negative for AFB
Drug TherapyDrug Therapy
Directly observed therapy (DOT)– Used with those clients who are noncompliant
and do not show signs of improvement after treatment. Noncompliance is major factor in multidrug resistance and treatment failures
– Provide drugs directly to the client and watch client swallow drugs
– Costly, but preferred to ensure adherence
Drug TherapyDrug TherapyVaccine– Bacille Calmette-Guérin (BCG) vaccine to prevent TB
is currently in use in many parts of the world
- once person receives this vaccine, will have a false testing with the TST (TB Skin Test). For assessment, must have chest x-ray.
Nursing Diagnosis labels Nursing Diagnosis labels appropriate for the client with appropriate for the client with
tuberculosistuberculosis
Ineffective airway clearanceImpaired gas exchangeNutrition, less than body requirementsActivity intoleranceRisk for noncomplianceKnowledge deficitIneffective health maintenance
Nursing AssessmentNursing Assessment
• Assess for:
– Productive cough
– Night sweats
– Afternoon temperature elevation
– Weight loss
IsolationIsolation
• negative flow room
• vent to outside
• masks, not ordinary– molded to fit face– patient wears a standard mask when outside
room
• ultraviolet light
General TeachingGeneral Teaching
• cover mouth and nose to cough
• dispose of tissues
• hand washing
• take meds as prescribed– 35% noncompliant
• monitor side effects
Criteria for Patient to return Criteria for Patient to return home (CDC)home (CDC)
• Follow up plan with local TB program• Patient on treatment with DOT arranged • No infants or children under 4 years old or
persons with immunocompromised condition at home
• All household members have already been exposed
• Pt willing to not travel outside home until sputum smear are (-)
Patient returning homePatient returning home
Should be instructed to:
•Cover mouth and nose with tissues when coughing or sneezing
•Sleep alone
•No visitors until non-infectious
Chronic ManagementChronic Management
• Follow up in 12 months
• 5% recurrence, relapse
• Test frequent contacts
• Factors which can cause relapse– immunosuppression– HIV/AIDS– prolonged debilitating illness
ComplianceCompliance
• Therapeutic, consistent relationship
• Understand lifestyle flexibility
• Education
• Reassurance, reduce social stigma
• Take meds at clinic
The EndThe End